Celgene's POLYMAST combined with dexamethasone approved by Health Canada Health Canada has approved POMALYST oral therapy in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen. POMALYST received priority review status by Health Canada due to the high unmet medical need that exists and the clinical value that the treatment brings to patients and physicians. POMALYST is expected to be commercially available in March. POMALYST was discovered and developed by Celgene.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.